Know Cancer

or
forgot password

Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Sandostatin for Patients With Advanced Neuroendocrine Cancers.


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Neuroendocrine Carcinoma, Neuroendocrine

Thank you

Trial Information

Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Sandostatin for Patients With Advanced Neuroendocrine Cancers.


- To determine overall response rate of patients with low grade neuroendocrine cancer
when treated with the combination of bevacizumab, pertuzumab and sandostatin LAR®.

- To determine the disease control rate (objective response + stable disease), time to
treatment progression, progression-free survival, and overall survival in patients with
advanced low grade neuroendocrine cancer when treated with bevacizumab, pertuzumab and
Sandostatin LAR® treatment.

- To define the toxicity and safety of the combination of bevacizumab, pertuzumab and
Sandostatin LAR® when used in patients with advanced low grade neuroendocrine cancer.


Inclusion Criteria:



1. Patients with biopsy-proven advanced, unresectable or metastatic, well-differentiated
(or low-grade) neuroendocrine carcinoma, including typical carcinoid, pancreatic
islet cell and other well-differentiated neuroendocrine carcinomas.

2. Patients with documented evidence of disease progression.

3. Patients currently receiving or previously treated with single agent Sandostatin LAR®
are eligible.

4. Patients must have >=1 unidimensional measurable lesion definable by MRI or CT scan.
Disease must be measurable per RECIST version 1.1 criteria.

5. Left Ventricular Ejection Fraction (LVEF) >=50% as determined by either ECHO or MUGA
<=6 weeks prior to study entry.

6. An ECOG Performance Status of 0-2.

7. Laboratory values as follows:

- ANC >=1500/μL

- Hgb >=9 g/dL

- Platelets >=100,000/μL

- AST/SGOT <=2.5 x ULN or <=5.0 x ULN in patients with liver metastases

- ALT/SGPT <=2.5 x ULN or <=5.0 x ULN in patients with liver metastases

- Bilirubin <=1.5 x ULN

- Creatinine <=2.0 mg/dL or calculated creatinine clearance >=50 mL/min

8. Patients >=18 years of age.

9. Patients must have a life expectancy >12 weeks.

10. Patient must be accessible for treatment and follow-up.

11. Women of childbearing potential must have a negative serum or urine pregnancy test
performed <=7 days prior to start of treatment. Women of childbearing potential must
use effective birth control measures during treatment. If a woman becomes pregnant or
suspects she is pregnant while participating in this study, she must agree to inform
her treating physician immediately.

12. Patients must be able to understand the nature of the study and give written informed
consent, and comply with study requirements

Exclusion Criteria:

1. Patients with poorly differentiated neuroendocrine carcinoma, highgrade
neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid, atypical carcinoid,
anaplastic carcinoid, and small cell carcinoma are not eligible.

2. Previous treatment with VEGF or EGFR inhibitors.

3. Cytotoxic chemotherapy, immunotherapy or radiotherapy <=4 weeks prior to study entry.

4. History or known presence of central nervous system (CNS) metastases.

5. Patients who have had a major surgical procedure (not including mediastinoscopy),
open biopsy, or significant traumatic injury <=4 weeks prior to beginning treatment.

6. Female patients who are pregnant or lactating.

7. History of hypersensitivity to active or inactive excipients of any component of
treatment (bevacizumab, sandostatin, and/or pertuzumab).

8. Patients with proteinuria at screening as demonstrated by urine dipstick for
proteinuria >=2+ (patients discovered to have >=2+ proteinuria on dipstick urinalysis
at baseline should undergo a 24-hour urine collection, and must demonstrate <=1 g of
protein/24 hours to be eligible).

9. Patients with a serious non-healing wound, active ulcer, or untreated bone fracture.

10. Patients with evidence of bleeding diathesis or significant coagulopathy (in the
absence of therapeutic anticoagulation).

11. Patients with history of hematemesis or hemoptysis (defined as having bright red
blood of ½ teaspoon or more per episode) <=1 month prior to study enrollment.

12. History of myocardial infarction or unstable angina <=6 months prior to beginning
treatment.

13. Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg
and /or diastolic blood pressure >100 mmHg while on antihypertensive medications).
Initiation of antihypertensive agents is permitted provided adequate control is
documented at least 1 week prior to Day of study treatment.

14. New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF).

15. Serious cardiac arrhythmia requiring medication.

16. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair, or
recent peripheral arterial thrombosis) <=6 months prior to Day 1 of treatment.

17. History of stroke or transient ischemic attack <=6 months prior to beginning
treatment.

18. Any prior history of hypertensive crisis or hypertensive encephalopathy.

19. History of abdominal fistula or gastrointestinal perforation <=6 months prior to Day
1 of beginning treatment.

20. Concurrent severe, intercurrent illness including, but not limited to, ongoing or
active infection, or psychiatric illness/social situations that would limit
compliance with study requirements.

21. Any known positive test for human immunodeficiency virus, hepatitis C virus or acute
or chronic hepatitis B infection.

22. Mental condition that would prevent patient comprehension of the nature of, and risk
associated with, the study.

23. Use of any non-approved or investigational agent <=28 days prior to administration of
the first dose of study drug. Patients may not receive any other investigational or
anti-cancer treatments while participating in this study.

24. Past or current history of neoplasm other than the entry diagnosis with the exception
of treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other
cancers cured by local therapy alone and a DFS >=5 years.

25. Infection requiring IV antibiotics.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine overall response rate of patients with low grade neuroendocrine cancer when treated with the combination of overall response rate

Outcome Description:

To determine overall response rate of patients with low grade neuroendocrine cancer when treated with the combination of bevacizumab, pertuzumab and sandostatin LAR®.

Outcome Time Frame:

18 months

Safety Issue:

No

Principal Investigator

Johanna C Bendell, S.B., M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Sarah Cannon Research Institute

Authority:

United States: Food and Drug Administration

Study ID:

SCRI GI 135

NCT ID:

NCT01121939

Start Date:

May 2010

Completion Date:

May 2013

Related Keywords:

  • Neuroendocrine Carcinoma
  • Neuroendocrine
  • advanced neuroendocrine
  • Gastrointestinal
  • Bevacizumab
  • Avastin
  • Pertuzumab
  • Omnitarg
  • 2C4
  • Sandostatin
  • Octreotide
  • Carcinoma
  • Carcinoma, Neuroendocrine

Name

Location

Florida Hospital Cancer InstituteOrlando, Florida  32804
Florida Cancer SpecialistsFort Myers, Florida  33901
Hematology-Oncology Associates of Northern NJMorristown, New Jersey  07962
Medical Oncology Associates of AugustaAugusta, Georgia  30901
Chattanooga Oncology Hematology AssociatesChattanooga, Tennessee  37404
Oncology Hematology Care, IncCincinnati, Ohio  45242